Loading patent…
AssigneesFred Hutchinson Cancer Research Center, Blaze Bioscience, Inc.
InventorsEmily June GIRARD, Colin CORRENTI, James OLSON, Natalie Winblade NAIRN, Mesfin Mulugeta GEWE, Christopher MEHLIN, Zachary CROOK, Roland STRONG, Scott Ronald PRESNELL
Estimating the term…
Peptides that are stable to denaturation and degradation by reducing agents, proteases, temperature, and low pH environments are disclosed. Pharmaceutical compositions and uses for peptides, peptide-active agent conjugates, and peptide-detectable agent conjugates comprising such peptides are also disclosed. Peptide compositions, peptide conjugate compositions, and pharmaceutical compositions can be formulated for various routes of delivery, such as oral delivery, and for deliver to various compartments of the body. Peptides of this disclosure are stable and display enhanced pharmacokinetics after such delivery.
1-372. (canceled)
A method comprising administering a compound comprising a peptide to a subject, wherein at least 70% of the peptide remains intact after exposure to pepsin at a temperature of at least 20° C. for at least 5 minutes and the peptide comprises at least 6 cysteine residues.
A compound comprising a peptide for use in a treatment of a gastrointestinal disorder, wherein at least 70% of the peptide remains intact after exposure to pepsin at a temperature of at least 20° C. for at least 5 minutes and the peptide comprises at least 6 cysteine residues.
A compound comprising a peptide and a permeation enhancer, wherein at least 70% of the peptide remains intact after exposure to pepsin at a temperature of at least 20° C. for at least 5 minutes and the peptide comprises at least 6 cysteine residues.
Dependencies are inferred from the claim text.